Microparticles of rifampicin: Comparison of pulmonary route with oral route for drug uptake by alveolar macrophages, phagocytosis activity and toxicity study in albino rats

Drug Delivery

Volumn 21, Issue 6, 2014, Pages 406-411

  Parikh, Rajesh ^a,b   Patel, Leena ^b   Dalwadi, Sonali ^a  

^a Department of Pharmaceutics and Pharmaceutical Technology ^*  (India)

^b CHAROTAR UNIVERSITY OF SCIENCE AND TECHNOLOGY   (India)

Author keywords

Drug delivery; Drug targeting; Dry powder inhalation; Spray drying; Tuberculosis

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; INDUCIBLE NITRIC OXIDE SYNTHASE; RIFAMPICIN; NITRIC OXIDE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANALYTIC METHOD; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; DRUG SOLUBILITY; DRUG UPTAKE; IN VITRO STUDY; IN VIVO STUDY; LIVER TOXICITY; LUNG ALVEOLUS MACROPHAGE; LUNG LAVAGE; MACROPHAGE ACTIVATION; NONHUMAN; PARTICLE SIZE; PHAGOCYTOSIS; PRIORITY JOURNAL; RAT; SPRAY DRYING; ANIMAL; COMPARATIVE STUDY; DRUG EFFECTS; INHALATIONAL DRUG ADMINISTRATION; LUNG; MEDICINAL CHEMISTRY; METABOLISM; MYCOBACTERIUM TUBERCULOSIS; ORAL DRUG ADMINISTRATION; PHYSIOLOGY; PROCEDURES; TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT; WISTAR RAT;

ADMINISTRATION, INHALATION; ADMINISTRATION, ORAL; ANIMALS; CHEMISTRY, PHARMACEUTICAL; LUNG; MACROPHAGES, ALVEOLAR; MYCOBACTERIUM TUBERCULOSIS; NITRIC OXIDE; PHAGOCYTOSIS; RATS; RATS, WISTAR; RIFAMPIN; TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84906540333     PISSN: 10717544     EISSN: 15210464     Source Type: Journal    
DOI: 10.3109/10717544.2013.851302     Document Type: Article

References (42)

1. Aillon K L, Xie Y, El-Gendy N, et al. (2009). Effects of nanomaterial physicochemical properties on in vivo toxicity. Adv Drug Deliv Rev 61:457-66.
2. Bailey MM, Berkland CJ. (2009). Nanoparticle formulations in pulmonary drug delivery. Med Res Rev 29:196-212.
3. Carlisle R, Galambos JT. (1979). The relationship between conventional liver tests, quantitative function tests, and histopathology in cirrhosis. Dig Dis Sci 24:358-62.
4. Chan JGY, Chan H-K, Prestidge CA, et al. (2013). A novel dry powder inhalable formulation incorporating three first-line anti-tubercular antibiotics. Eur J Pharm Biopharm 83:285-92.
5. Chow AL, Tong HY, Chattopadhyay P, Shekunov B. (2007). Particle engineering for pulmonary drug delivery. Pharm Res 24: 411-37.
6. Coowanitwong I, Arya V, Kulvanich P, Hochhaus GN. (2008). Slow release formulations of inhaled rifampin. AAPS J 10:342-8.
7. Du Toit LC, Pillay V, Danckwerts MP. (2006). Tuberculosis chemotherapy: current drug delivery approaches. Respir Res 7:118-35.
8. Dube D, Agrawal GP, Vyas SP. (2012). Tuberculosis: from molecular pathogenesis to effective drug carrier design. Drug Discov Today 17: 760-73.
9. Duncan K, Barry III CE. (2004). Prospects for new antitubercular drugs. Curr Opin Microbiol 7:460-5.
10. Gohel MC, Sarvaiya KG. (2007). A novel solid dosage form of rifampicin and isoniazid with improved functionality. AAPS PharmSciTech 8:E133-9.
11. Hirota K, Tomoda K, Inagawa H, et al. (2008). Stimulation of phagocytic activity of alveolar macrophages toward artificial microspheres by infection with mycobacteria. Pharm Res 25:1420-30.
12. Kaur J, Muttil P, Verma RK, et al. (2008). A hand-held apparatus for nose-only exposure of mice to inhalable microparticles as a dry powder inhalation targeting lung and airway macrophages. Eur J Pharm Sci 34:56-65.
13. Kleinnijenhuis J, Oosting M, Joosten LA, et al. (2011). Innate immune recognition of Mycobacterium tuberculosis. Clin Dev Immunol 11: 1-12.
14. Kolodziej H, Kiderlen AF. (2007). In vitro evaluation of antibacterial and immunomodulatory activities of Pelargonium reniforme, Pelargonium sidoides and the related herbal drug preparation EPs 7630. Phytomedicine 14:18-26.
15. Lal S, Singhal S, Burley D, Crossley G. (1972). Effect of rifampicin and isoniazid on liver function. BMJ 1:148-50.
16. Maartens G, Wilkinson RJ. (2007). Tuberculosis. Lancet 370: 2030-43.
17. Marcinkiewicz J. (1997). Nitric oxide and antimicrobial activity of reactive oxygen intermediates. Immunopharmacology 37:35-41.
18. Marques MR, Loebenberg R, Almukainzi M. (2011). Simulated biological fluids with possible application in dissolution testing. Dissolution Technol 18:15-28.
19. Misra A, Hickey AJ, Rossi C, et al. (2011). Inhaled drug therapy for treatment of tuberculosis. Tuberculosis 91:71-81.
20. Murphy MP. (1999). Nitric oxide and cell death. Biochim Biophys Acta 1411:401-14.
21. Muttil P, Kaur J, Kumar K, et al. (2007). Inhalable microparticles containing large payload of anti-tuberculosis drugs. Eur J Pharm Sci 32:140-50.
22. Nathan CF, Hibbs Jr JB. (1991). Role of nitric oxide synthesis in macrophage antimicrobial activity. Curr Opin Immunol 3:65-70.
23. O'hara P, Hickey AJ. (2000). Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: manufacture and characterization. Pharm Res 17:955-61.
24. Ober CA, Kalombo L, Swai H, Gupta RB. (2012). Preparation of rifampicin/lactose microparticle composites by a supercritical antisolvent-drug excipient mixing technique for inhalation delivery. Powder Technol 236:132-8.
25. Ohashi K, Kabasawa T, Ozeki T, Okada H. (2009). One-step preparation of rifampicin/poly (lactic-co-glycolic acid) nanoparticle-containing mannitol microspheres using a four-fluid nozzle spray drier for inhalation therapy of tuberculosis. J Control Release 135:19-24.
26. Pandey R, Khuller GK. (2005). Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis. Tuberculosis 85:227-34.
27. Ricciardolo FL, Sterk PJ, Gaston B, Folkerts G. (2004). Nitric oxide in health and disease of the respiratory system. Physiol Rev 84:731-65.
28. Roa WH, Azarmi S, Al-Hallak MHDK, et al. (2011). Inhalable nanoparticles, a non-invasive approach to treat lung cancer in a mouse model. J Control Release 150:49-55.
29. Rojanarat W, Changsan N, Tawithong E, et al. (2011). Isoniazid proliposome powders for inhalation preparation, characterization and cell culture studies. Int J Mol Sci 12:4414-34.
30. Sen H, Jayanthi S, Sinha R, et al. (2003). Inhalable biodegradable microparticles for target-specific drug delivery in tuberculosis and a process thereof. U.S. Patent Application 10/685,567.
31. Sharma R, Muttil P, Yadav AB, et al. (2007). Uptake of inhalable microparticles affects defence responses of macrophages infected with Mycobacterium tuberculosis H37Ra. J Antimicrob Chemother 59: 499-506.
32. Shishoo CJ, Shah SA, Rathod IS, et al. (1999). Stability of rifampicin in dissolution medium in presence of isoniazid. Int J Pharm 190:109-23.
33. Son Y-J, Mcconville JT. (2011). A new respirable form of rifampicin. Eur J Pharma Biopharm 78:366-76.
34. Sosnik A, Carcaboso ÃNM, Glisoni RJ, et al. (2010). New old challenges in tuberculosis: potentially effective nanotechnologies in drug delivery. Adv Drug Deliv Rev 62:547-59.
35. Suarez S, O'hara P, Kazantseva M, et al. (2001). Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: screening in an infectious disease model. Pharm Res 18:1315-19.
36. Sung JC, Padilla DJ, Garcia-Contreras L, et al. (2009). Formulation and pharmacokinetics of self-assembled rifampicin nanoparticle systems for pulmonary delivery. Pharm Res 26:1847-55.
37. Verma RK, Kaur J, Kumar K, et al. (2008). Intracellular time course, pharmacokinetics, and biodistribution of isoniazid and rifabutin following pulmonary delivery of inhalable microparticles to mice. Antimicrob Agents Chemother 52:3195-201.
38. Vyas S, Kannan M, Jain S, et al. (2004). Design of liposomal aerosols for improved delivery of rifampicin to alveolar macrophages. Int J Pharm 269:37-49.
39. Xie Y, Aillon KL, Cai S, et al. (2010). Pulmonary delivery of cisplatinhyaluronan conjugates via endotracheal instillation for the treatment of lung cancer. Int J Pharm 392:156-63.
40. Young DB. (2001). Stimulate the phagocytes. Tuberculosis (Edinb) 81: 257-8.
41. Zhang S, Kawakami K. (2010). One-step preparation of chitosan solid nanoparticles by electrospray deposition. Int J Pharm 397: 211-17.
42. Zhang Y, Li A, Wang Z, et al. (2008). Antimetastatic activities of pegylated liposomal doxorubicin in a murine metastatic lung cancer model. J Drug Target 16:679-87.